Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study assessing AT-H201 in COVID-19 patients

Next Previous
Trial Profile

A study assessing AT-H201 in COVID-19 patients

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 19 Aug 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AT-H201 (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Acronyms HOPE
  • Sponsors Atossa Therapeutics

Most Recent Events

  • 13 Aug 2020 According to an Atossa Therapeutics media release, the company expects to receive regulatory approval and commence enrollment in 2020.
  • 07 May 2020 According to an Atossa Therapeutics media release, the FDA has requested, among other things, that Atossa submit additional pre-clinical and other information on AT-H201 before approving the study. Atossa is in the process of gathering the data and information requested and plans to provide it to the FDA as soon as possible. There can be no assurance that Atossa will be able to provide the information requested by the FDA nor that the FDA will approve the COVID-19 HOPE Study.
  • 27 Apr 2020 According to an Atossa Therapeutics media release, the company announced that it has contracted with NYC Health + Hospitals/Metropolitan in New York City to conduct this study. Getaw Hassen is the principal investigator of this study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top